There have been many scientific studies, clinical trials, and reviews on immunotherapy in GC, including projects focusing on immune checkpoint molecules (ICPMs) and immune checkpoint inhibitors [3] and other biomarkers in GC like HER2 [4], CEA [5], Ca19.9 [6], miRNA [7], etc. Despite the enormous progress in research and discovery of modern therapies based on new molecular targets, there is still a lack of universal strategies for GC patients, hence the continuous search for new and promising therapeutic targets. This evidence concerns the gene ERBB2 and gastric cancer.